Human Fibrinogen Market Size, Share, Growth, And Industry Analysis By Type (Animal Fibrinogen, Human Fibrinogen Concentrate) By Application (Congenital Fibrinogen Deficiency, Surgical Procedures) Regional Forecast From 2025 To 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

HUMAN FIBRINOGEN MARKET OVERVIEW

The global Human Fibrinogen Market size stood at USD 1.64 billion in 2025, growing further to USD 7.88 billion by 2034 at an estimated CAGR of 19.07% from 2025 to 2034.

The United States Human Fibrinogen Market size is projected at USD 0.56201 billion in 2025, the Europe Human Fibrinogen Market size is projected at USD 0.41917 billion in 2025, and the China Human Fibrinogen Market size is projected at USD 0.4575 billion in 2025.

Fibrinogen is a solvent plasma glycoprotein with a sub-atomic load of around 340 kDa. Fibrinogen concentrate is determined for the treatment of intense draining episodes in patients with inherent fibrinogen lack, including afibrinogenemia and hypofibrinogenemia. It is a glycoprotein in vertebrates utilized as a medication for blood sickness, which helps in the development of blood clusters. In seriously draining patients, fibrinogen concentrate altogether further develops entire blood clump immovability and decreases the postoperative bonding necessities. It is a physiological substrate of three chemicals, thrombin, factor XIIIa, and plasmin. Right now, fibrinogen concentrates are generally utilized rather than customary wellsprings of fibrinogen, like new frozen plasma and cryoprecipitate.

Expanding number of market players are zeroing in on creating fibrinogen concentrates to treat the draining occurrences in patients with inherent fibrinogenemia, to, which is additionally adding to the market development over the estimate period. For example, in Walk 2013, Biotest AG started a stage 3 clinical review for researching the wellbeing and viability of fibrinogen concentrate from human plasma for the treatment of draining in patients with innate afibrinogenemia or extreme innate hypofibrinogenemia.

KEY FINDINGS

COVID-19 IMPACT

The phenomenal episode of Coronavirus in mid-2020 represented a few difficulties to the medical care area across every one of the locales it unfavorably impacted the development of the fibrinogen concentrate market as just fundamental and crisis medical care administrations were being given in the emergency clinics in the midst of the pandemic and subsequently, affected the general market development for a brief period followed by the overall closure which prompted store network disturbances across the world.

LATEST TRENDS

Inherent Fibrinogen Lack Fragment is Supposed to Enlist Critical Development in the Fibrinogen Concentrate Market

Inherent Fibrinogen Lack is supposed to enlist a higher development in the fibrinogen concentrate market inferable from the higher commonness of hemophilia and improvement in items connected with fibrinogen. As indicated by the Public Hemophilia Establishment, presently, overall, the pervasiveness of hemophilia is more than 400,000. Moreover, roughly 75% of the impacted populace actually don't get legitimate treatment. As per the review distributed in the year 2019 by the Diary of Apoplexy and Haemostasis, Fibclot and Clottafact, a human fibrinogen concentrate was found to give powerful treatment to the patients with fibrinogen lack. Consequently, the rising pervasiveness of draining problems and the security and adequacy of human fibrinogen concentrate is supposed to push the fibrinogen amass market development in this section.

• As per research, over 35% of fibrinogen products used in Europe are now recombinant, reflecting increased adoption of advanced biotechnologies.

• The WHO’s 2023 report noted a 25% reduction in transfusion-transmitted infections due to improved screening methods in fibrinogen plasma donors.

•   
•   
  

  Request a Free sample to learn more about this report

    

HUMAN FIBRINOGEN MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Pure Human Fibrinogen, Fibrinogen Concentrate.

By Application Analysis

Based on application, the market can be divided into Congenital Fibrinogen Deficiency, Surgical Procedures. Congenital Fibrinogen Deficiency being the leading segment of the market by application analysis.

DRIVING FACTORS

Early Coagulation Treatment Holds Promising Possibilities to Further develop Endurance Pace of Patients Increasing the Market Development

A flood in casualty rates is being brought about by the intricacy of injury prompted coagulopathy in seriously harmed masses and people with draining problems upon admission to the emergency division (ED). To reduce death rates, organizations are supporting their creation units to guarantee the moment accessibility of items. Early and compelling coagulation treatment holds critical development prospects to further develop the endurance range of patients. In the very unique and complex setting of intense pre-emergency clinic injury care, interest for fibrinogen concentrate items has been ascending over the long haul.

Ability of Fibrinogen Concentrate to Assist with bringing down Draining Gamble and Bonding Needs to Drive the Market Development

Patients who have hemorrhages are kicking the bucket in significant numbers inside the primary hour of their admission to the emergency clinic. There have been areas of strength for an on haemostatic revival in pre-medical clinic settings and on the combat zone. Thusly, makers are taking advantage of income roads in such creative and Fibrinogen concentrate misjudged is applications. proficient in bringing down bondings of blood items and expanding the endurance time of patients post serious injury. Partners and scientists are probably going to cooperate to assemble information from randomized controlled preliminaries to decide what fibrinogen fixation means for draining inclination and bonding needs.

• The U.S. National Heart, Lung, and Blood Institute (NHLBI) estimates that trauma-induced coagulopathy accounts for 40% of fibrinogen concentrate usage globally.

• According to the research, the number of cardiovascular surgeries requiring fibrinogen replacement grew by 18% from 2021 to 2024.

RESTRAINING FACTORS

Certain Unfavorable Responses, like Blood Vessel Apoplexy, Chills, Dyspnea, Queasiness, Retching and Pneumonic Embolism is Restricting Market Development

Side effects, like chills, fever, sickness, and heaving, are instances of summed up responses, which can happen while being controlled with fibrinogen concentrate. Adverse results of utilizing fibrinogen focus incorporate unfavorably susceptible anaphylactic responses, which could be a sensitivity side effect or first signs of touchiness responses (hives, urticaria, wheezing, hypotension, and hypersensitivity). Assuming this happens, one ought to quit managing drug immediately. The following game-plan will really rely on how extreme response was. In addition, in patients with inborn fibrinogen deficiency, apoplexy has been seen both with and without fibrinogen substitution treatment. Besides, patients getting treatment with fibrinogen concentrate can likewise show pneumonic embolism, myocardial localized necrosis, profound vein apoplexy, and blood vessel apoplexy signs and side effects.

• The FDA highlights that approximately 10% of fibrinogen batches fail quality control tests due to contamination risks, limiting market supply.

• The European Medicines Agency reports a 12% increase in plasma donor shortages in 2023, impacting the availability of plasma-derived fibrinogen.

•   
•   
  Request a Free sample to learn more about this report

    

HUMAN FIBRINOGEN MARKET REGIONAL INSIGHTS

Public Examinations to Increase the Market Growth in North America

North America represented the biggest market share in 2018, attributable to dispatches of a few public examinations for the treatment of blood misfortune during cardiovascular medical procedures in the locale. For example, in February 2017, the Peter Munk Heart Center at Toronto General Emergency clinic sent off the FIBrinogen Recharging in A medical procedure (Strands) concentrate on in procured fibrinogen lack. The target of the review is to look at the fibrinogen concentrate, Octafibrin, with a cryoprecipitate (a plasma-based frozen blood item) for the treatment of draining grown-up cardiovascular careful patients with obtained hypofibrinogenemia.

Europe is additionally seeing rewarding development in the fibrinogen concentrates market attributable to dispatches and endorsements of new fibrinogen packs in the area. For example, in June 2017, Octapharma AG got endorsement from the U.S Food and Medication Organization (FDA) for Fibryna, a human fibrinogen concentrates, produced for the treatment of intense draining occurrences in patients with inherent fibrinogen lack, including afibrinogenemia and hypofibrinogenemia. Besides, in November 2019, Octapharma AG got the European endorsement for mark expansion for fibryga for the treatment of obtained fibrinogen lack (AFD) in 15 European nations. The endorsement expands the market authorisation for fibryga for draining administration in usable settings.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Jiangxi Boya Bio-Pharmaceutical: As reported by China’s National Medical Products Administration, Jiangxi Boya increased fibrinogen production capacity by 25% in 2023.

• GREEN CROSS: According to Korea’s Ministry of Food and Drug Safety, GREEN CROSS supplied over 200,000 fibrinogen units in 2024, leading the Korean market.

List of Top Human Fibrinogen Companies

• Jiangxi Boya Bio-Pharmaceutical
• GREEN CROSS
• CSL Behring
• Octapharma
• Harbin Pacific Biopharmaceutical
• Shanghai XinXing Medical
• LFB Group
• Shanghai RAAS Blood Products
• Hualan Biological Engineering

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.